729611-19-2

Upstream product

• 494224-49-6 (R)-ethyl 4-(tert-butoxycarbonylamino)-5-oxopentanoate 
• 1380347-59-0 ethyl (4R,5E,7S)-8-(3-(5-chloro-1,3-benzoxazol-2-yl)phenyl)-7-hydroxy-4-((tert-butyloxycarbonyl)amino)-5-octenoate 
• 597577-64-5 ethyl 2-[(2,2-diethoxyethyl)thio]-1,3-thiazole-4-carboxylate 
• 597577-65-6 ethyl 2-[(2-oxoethyl)thio]-1,3-thiazole-4-carboxylate 
• 1380347-35-2 2-(3-iodophenyl)-5-chloro-1,3-benzoxazole 
• 1380347-36-3 N-methoxy-N-methyl-2-[3-(5-chloro-1,3-benzoxazol-2-yl)phenyl]acetamide 
• 1225168-81-9 C₁₅H₁₀ClNO₃ 
• 618-51-9 3-Iodobenzoic acid 

Relevant academic research and scientific papers

Synthesis and evaluation of γ-lactam analogs of PGE2 as EP4 and EP2/EP4 agonists

To identify topically effective EP4 agonists and EP2/EP4 dual agonists with excellent subtype selectivity, further optimization of the 16-phenyl ω-chain moiety of the γ-lactam 5-thia prostaglandin E analog and the 2-mercaptothiazole-4-carboxylic acid anal

8-AZAPROSTAGLANDIN DERIVATIVES AND MEDICINAL USES THEREOF

The pharmaceutical composition comprising the compound of the invention having 8-azaprostaglandin skeleton represented by formula (I) (wherein, all the symbols have the same meanings as that of the specification.) a salt thereof, a solvate thereof or a cyclodextrin clathrate thereof, or a prodrug thereof and them as active ingredient have EP4 agonistic action and thus are considered useful for the prevention and/or treatment of immunological diseases, asthma, neuronal cell death, arthritis, lung failure, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardial ischemia, systemic inflammatory response syndrome, sepsis, hemophagous syndrome, macrophage activation syndrome, Still''s disease, Kawasaki disease, burn, systemic granulomatosis, ulcerative colitis, Crohn''s disease, hypercytokinemia at dialysis, multiple organ failure, shock and glaucoma, etc. Furthermore, the compounds also have an action of accelerating bone formation, so it is expected to be useful for the prevention and/or treatment of diseases associated with loss in bone mass, for example, primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget''s disease, bone loss, osteonecrosis, bone formation after bone operation, alternative treatment for bone grafting.